| 1 | 13:30-14:00 | 致辞 |
开幕式致辞 |
|
||||||||||||||
| 1 | 14:00-14:20 | 大会报告 |
CAR-T细胞治疗肝癌的初步经验 |
|
||||
| 2 | 14:20-14:40 | 大会报告 |
重症感染与出凝血异常 |
|
||||
| 3 | 14:40-15:00 | 大会报告 |
Blockade of polyamines enable PD-L1/PD-1 signaling to augment donor T ferroptosis in tissues to prevent GVHD while preserving GVL activity |
|
||||
| 4 | 15:00-15:20 | 大会报告 |
Acute lymphoblastic leukemia: insights from single-cell sequencing analysis |
|
||||
| 5 | 15:20-15:40 | 大会报告 |
异基因造血干细胞移植治疗混合表型白血病进展--近期工作进展 |
|
||||
| 6 | 15:40-16:00 | 大会报告 |
出血性疾病的临床转化研究 |
|
||||
| 7 | 16:00-16:20 | 大会报告 |
细胞治疗的未来趋势 |
|
||||
| 1 | 16:20-16:40 | 大会报告 |
剪接因子SRSF1调控LCK外显子跳跃诱导Treg分化在ITP中的作用机制研究 |
|
||||
| 2 | 16:40-17:00 | 大会报告 |
AML的精准治疗 |
|
||||
| 3 | 17:00-17:20 | 大会报告 |
难治性白血病微环境问题及临床应对策略 |
|
||||
| 4 | 17:20-17:40 | 大会报告 |
TKI时代CML的停药与妊娠 |
|
||||
| 1 | 08:00-08:10 | 致辞 |
开幕致辞 |
|
||||||||
| 2 | 08:10-08:17 | 口头报告 |
Peritoneal effusion as a marker of disease severity in secondary hemophagocytic lymphohistiocytosis: clinical and immunological insights |
|
||||||||
| 3 | 08:17-08:24 | 口头报告 |
Multicenter Validation and Optimization of the Hemophagocytic Lymphohistiocytosis Threshold Model |
|
||||||||
| 4 | 08:24-08:31 | 口头报告 |
Epigenetic dysregulation of pseudogene ZNF300P1 predicts advanced stage and aggressive phenotype in myelodysplastic neoplasms and acute myeloid leukemia |
|
||||||||
| 5 | 08:31-08:38 | 口头报告 |
PRKCE maintains BCR signaling dependency and cell-cycle adaptation to drive BTK inhibitor resistance in Waldenström Macroglobulinemia |
|
||||||||
| 6 | 08:38-08:45 | 口头报告 |
PHF19 Drives IMiDs Resistance by A Reciprocal Epigenetic-transcriptional Adaptive Circuit in Multiple Myeloma |
|
||||||||
| 7 | 08:45-08:50 |
第一组专家点评 |
|
|||||||||
| 8 | 08:50-08:57 | 口头报告 |
Clinical characteristics and molecular heterogeneity of EBV-positive lymphoma |
|
||||||||
| 9 | 08:57-09:04 | 口头报告 |
Prognostic Relevance of Residual-Based Discordance Between Serum Soluble B-Cell Maturation Antigen and Tumor-Burden Surrogates in Newly Diagnosed Multiple Myeloma |
|
||||||||
| 10 | 09:04-09:11 | 口头报告 |
Unraveling chronic myelomonocytic leukemia (CMML): clinical and therapeutic insights from a ten-year multi-center retrospective cohort |
|
||||||||
| 11 | 09:11-09:18 | 口头报告 |
Subtype distribution and co-mutation landscape of CSF3R mutations in myeloid neoplasms: a multicenter retrospective study |
|
||||||||
| 12 | 09:18-09:25 | 口头报告 |
Blood Metagenomic Next-Generation Sequencing Reveals Prognostic Patterns in Mucormycosis and Guides Antifungal Therapy |
|
||||||||
| 13 | 09:25-09:30 | 点评 |
第二组专家点评 |
|
||||||||
| 14 | 09:30-09:37 | 口头报告 |
Clinical Characteristics of Primary Central Nervous System Diffuse Large B-Cell Lymphoma germinal center B-cell-like Subtype |
|
||||||||
| 15 | 09:37-09:44 | 口头报告 |
Augmenter of Liver Regeneration Suppresses Ferroptosis via the AMPK/SREBP1/FADS2 Axis to Promote Chemoresistance in T-ALL |
|
||||||||
| 16 | 09:44-09:51 | 口头报告 |
Multi-Omics Reveals the Immune Microenvironment of Ruxolitinib-Resistant Primary Myelofibrosis and the Preclinical Efficacy of CDK2 Inhibitor-Based Combinations against Myeloproliferative Neoplasms Transformed to AML |
|
||||||||
| 17 | 09:51-09:58 | 口头报告 |
Clinical phenotype, in-hospital mortality, and treatment pathways in thrombotic thrombocytopenic purpura: a two-decade single-centre cohort study |
|
||||||||
| 18 | 09:58-10:03 | 点评 |
第三组专家点评 |
|
||||||||
| 19 | 10:03-10:10 | 口头报告 |
Venetoclax plus azacitidine and lenalidomide (VAL) for newly diagnosed elderly patients with acute myeloid leukemia/myelodysplastic syndromes: a single-center, prospective, single-arm clinical study |
|
||||||||
| 20 | 10:10-10:17 | 口头报告 |
Preliminary Study on the Effects and Mechanisms of Hedyotis diffusa Willd. against Acute Myeloid Leukemia Based on Network Pharmacology, Molecular Docking and in Vitro Experimental Validation |
|
||||||||
| 21 | 10:17-10:24 | 口头报告 |
Venetoclax plus azacitidine and cytarabine in younger unfit patients with newly AML: A cohort from a multi-centre, open-label, single-arm, phase 2 trial |
|
||||||||
| 22 | 10:24-10:31 | 口头报告 |
β-sitosterol suppresses JAK2-driven myeloproliferative neoplasm cell growth in association with STAT1 upregulation and BCL-2 downregulation |
|
||||||||
| 23 | 10:31-10:38 | 口头报告 |
Systemic Mastocytosis in China: A Multicenter Real-World Study of Clinical Features, Molecular Alterations, Treatment Patterns, and Survival Outcomes |
|
||||||||
| 24 | 10:38-10:43 | 点评 |
第四组专家点评 |
|
||||||||
| 25 | 10:43-10:50 | 口头报告 |
Addition of a FLT3 inhibitor to hypomethylating therapy plus venetoclax in newly diagnosed, unfit FLT3-ITD acute myeloid leukaemia: a multicentre retrospective study |
|
||||||||
| 26 | 10:50-10:57 | 口头报告 |
Etoposide plus thiotepa-busulfan-fludarabine conditioning for allogeneic transplantation in high-risk EBV-associated NK/T-cell malignancies |
|
||||||||
| 27 | 10:57-11:04 | 口头报告 |
Early intervention with the oropharyngeal probiotic BP-OM1 for infection prophylaxis in patients with diffuse large B-cell lymphoma undergoing autologous haematopoietic stem-cell transplantation: a multicentre observational study |
|
||||||||
| 28 | 11:04-11:11 | 口头报告 |
Latent Classes and Influencing Factors of Fear of Cancer Recurrence before Hematopoietic Stem Cell Transplantation |
|
||||||||
| 29 | 11:11-11:16 | 点评 |
第五组专家点评 |
|
||||||||
| 30 | 11:16-11:23 | 口头报告 |
Pre-clinical development of CAR-T cells targeting a lytic EBV antigen gp350 for therapy of EBV-positive diffuse large B-cell lymphoma |
|
||||||||
| 31 | 11:23-11:30 | 口头报告 |
Efficacy and safety of a novel third-generation fully humanized tandem CD19/CD22 dual-targeted CAR-T with TLR2 costimulation for relapsed/refractory diffuse large B-cell lymphoma |
|
||||||||
| 32 | 11:30-11:37 | 口头报告 |
Efficacy of Inati-cel Consolidation Therapy in Allogeneic Transplant-Ineligible Adolescent and Adult Patients with B-ALL |
|
||||||||
| 33 | 11:37-11:44 | 口头报告 |
Sexual health status and nursing needs of lymphoma patients during treatment: gender differences |
|
||||||||
| 34 | 11:44-11:49 | 点评 |
第六组专家点评 |
|
||||||||
| 35 | 11:49-11:56 | 总结 |
总结 |
|
||||||||
| 1 | 08:00-08:10 | 致辞 |
主席致辞 |
|
||||||||||||
| 2 | 08:10-08:25 | 专题发言 |
异基因移植治疗PMF研究进展 |
|
||||||||||||
| 3 | 08:25-08:40 | 专题发言 |
急性白血病 |
|
||||||||||||
| 1 | 08:40-08:45 |
篇章开场 |
|
|||||||||||||
| 2 | 08:45-09:00 | 专题发言 |
2026慢性髓细胞性白血病(CML)诊治进展 |
|
||||||||||||
| 3 | 09:00-09:40 | 辩论 |
正方:3G-TKI应该成为CML-CP二线治疗的首选方案 |
|
||||||||||||
| 4 | 09:00-09:40 | 辩论 |
反方:3G-TKI不该成为CML-CP二线治疗的首选方案 |
|
||||||||||||
| 5 | 09:40-09:55 | 讨论 |
点评提问 |
|
||||||||||||
| 1 | 09:55-10:00 |
篇章开场 |
|
|||||||||||||
| 2 | 10:00-10:15 | 专题发言 |
2026费城染色体阳性急性淋巴细胞白血病(Ph+ ALL)诊断及一线诱导治疗进展 |
|
||||||||||||
| 3 | 10:15-10:55 | 辩论 |
正方:Ph+ ALL一线诱导应该去化疗 |
|
||||||||||||
| 4 | 10:15-10:55 | 辩论 |
反方:Ph+ ALL一线诱导不该去化疗 |
|
||||||||||||
| 5 | 10:50-11:10 | 点评 |
点评提问 |
|
||||||||||||
| 1 | 11:10-11:15 |
篇章开场 |
|
|||||||||||||
| 2 | 11:15-11:30 | 专题发言 |
2026费城染色体阳性急性淋巴细胞白血病(Ph+ ALL)移植相关进展 |
|
||||||||||||
| 3 | 11:30-12:10 | 辩论 |
正方:一线Ph+ ALL仍需要移植 |
|
||||||||||||
| 4 | 11:30-12:10 | 辩论 |
反方:一线Ph+ ALL不需要移植 |
|
||||||||||||
| 5 | 12:10-12:25 | 讨论 |
点评提问 |
|
||||||||||||
| 1 | 13:30-13:40 | 致辞 |
开幕致辞 |
|
||||||||
| 1 | 13:40-14:00 | 专题发言 |
局部递送CART细胞的抗肿瘤作用及机制 |
|
||||||||||
| 2 | 14:00-14:20 | 专题发言 |
CAR-T细胞技术进化 |
|
||||||||||
| 3 | 14:20-14:40 | 专题发言 |
昼夜节律调控免疫治疗 |
|
||||||||||
| 4 | 14:40-15:00 | 专题发言 |
从 TCR-T 与 CAR-T 的比较探讨下一代 T 细胞治疗策略 |
|
||||||||||
| 5 | 15:00-15:10 | 讨论 |
讨论 |
|
||||||||||
| 1 | 15:10-15:30 | 专题发言 |
成人急性淋巴细胞白血病一线免疫靶向治疗 |
|
||||||||||
| 2 | 15:30-15:50 | 专题发言 |
造血再生与维持 |
|
||||||||||
| 3 | 15:50-16:10 | 专题发言 |
多发性骨髓瘤T细胞重定向治疗 |
|
||||||||||
| 4 | 16:10-16:30 | 专题发言 |
冷冻电镜解析DNA双链断裂修复蛋白分子机制及人工设计修复核心蛋白抑制剂增效基因编辑效率 |
|
||||||||||
| 5 | 16:30-16:40 | 讨论 |
讨论 |
|
||||||||||
| 1 | 16:40-16:50 | 总结 |
闭幕总结 |
|
||||||||
| 1 | 08:00-08:10 | 致辞 |
开幕致辞 |
|
||||||||
| 1 | 08:10-08:30 | 专题发言 |
T细胞疗法在淋巴瘤的应用 |
|
||||||
| 2 | 08:30-08:50 | 专题发言 |
噬血细胞综合征的创新治疗 |
|
||||||
| 3 | 08:50-09:10 | 专题发言 |
T细胞淋巴瘤免疫治疗策略 |
|
||||||
| 4 | 09:10-09:30 | 专题发言 |
nk/t细胞淋巴瘤的研究进展 |
|
||||||
| 5 | 09:30-09:50 | 讨论 |
讨论 |
|
||||||
| 1 | 10:10-10:30 | 专题发言 |
新药时代自体造血干细胞移植治疗淋巴瘤的挑战 |
|
||||||
| 2 | 10:30-10:50 | 专题发言 |
中枢淋巴瘤经验总结和诊疗思考 |
|
||||||
| 3 | 10:50-11:10 | 专题发言 |
原发中枢神经系统淋巴瘤诊疗进展 |
|
||||||
| 4 | 11:10-11:30 | 专题发言 |
EBV相关淋巴组织性疾病的免疫治疗 |
|
||||||
| 5 | 11:30-11:50 | 讨论 |
讨论 |
|
||||||
| 1 | 13:30-13:40 | 致辞 |
开幕致辞 |
|
||||||||||
| 1 | 13:40-14:00 | 专题发言 |
难治AIHA治疗进展 |
|
||||
| 2 | 14:00-14:10 | 讨论 |
讨论环节 |
|
||||
| 3 | 14:10-14:30 | 专题发言 |
大颗粒淋巴细胞白血病(JAKi) |
|
||||
| 4 | 14:30-14:40 | 讨论 |
讨论环节 |
|
||||
| 5 | 14:40-15:00 | 专题发言 |
化疗后继发再障的诊治 |
|
||||
| 6 | 15:00-15:10 | 讨论 |
讨论环节 |
|
||||
| 1 | 15:10-15:30 | 专题会发言 |
指南赋能临床:2025ITP指南下促血小板生成药物定位与证据支撑 |
|
||||
| 1 | 15:30-15:50 | 专题发言 |
从ITP指南更新到循证实践 |
|
||||
| 2 | 15:50-16:00 | 讨论 |
讨论环节 |
|||||
| 3 | 16:00-16:20 | 专题会发言 |
专题会:阿伐曲泊帕治疗ITP临床研究进展 |
|
||||
| 4 | 16:20-16:40 | 专题发言 |
CD38单抗治疗ITP研究进展 |
|
||||
| 5 | 16:40-16:50 | 讨论 |
讨论环节 |
|
||||
| 6 | 16:50-17:10 | 专题发言 |
PNH临床需求与规范化诊疗进展 |
|
||||
| 7 | 17:10-17:20 | 讨论 |
讨论环节 |
|
||||
| 1 | 08:00-08:20 | 致辞 |
开幕致辞 |
|
||||||||||
| 2 | 08:20-08:40 |
项目启动 |
|
|||||||||||
| 1 | 08:40-09:00 | 专题发言 |
多发性骨髓瘤治疗目标再定义:从深度缓解到持续获益 |
|
||||
| 2 | 09:00-09:05 | 讨论 |
讨论 |
|||||
| 3 | 09:05-09:25 | 专题发言 |
EHA前沿速递:新诊断MM的治疗新进展 |
|
||||
| 4 | 09:25-09:30 | 讨论 |
讨论 |
|
||||
| 5 | 09:30-09:50 | 专题会发言 |
双抗治疗 RRMM 新进展 |
|
||||
| 6 | 09:50-09:55 | 讨论 |
讨论 |
|
||||
| 7 | 09:55-10:15 | 专题发言 |
RRMM免疫治疗的探索之路 |
|
||||
| 8 | 10:15-10:20 | 讨论 |
讨论 |
|||||
| 1 | 10:20-10:40 | 专题发言 |
GPRC5D靶点新进展 |
|
||||
| 2 | 10:40-10:45 | 讨论 |
讨论 |
|
||||
| 3 | 10:45-11:05 | 专题发言 |
BCMA×CD3双抗 在高危特征RRMM患者中的应用及探索 |
|
||||
| 4 | 11:05-11:10 | 讨论 |
讨论 |
|
||||
| 5 | 11:10-11:30 | 专题发言 |
高危多发性骨髓瘤诊疗进展 |
|
||||
| 6 | 11:30-11:35 | 讨论 |
讨论 |
|
||||
| 7 | 11:35-11:55 | 专题会发言 |
专题会:靶向BCMA治疗破局RRMM困境 |
|
||||
| 1 | 14:00-14:10 | 致辞 |
开幕致辞 |
|
||||||||||
| 1 | 14:10-14:25 | 专题发言 |
中华医学杂志英文版 血液肿瘤高质量学术成果前瞻 &“避坑”指南 |
|
||||||
| 2 | 14:25-14:40 | 专题发言 |
新药迭代,旧问未解?——智能体驱动的MM研究选题挖掘 |
|
||||||
| 3 | 14:40-14:50 | 讨论 |
共探:2026 MM领域未尽之需 |
|
||||||
| 1 | 14:50-15:10 | 专题发言 |
血液领域高质量研究1 |
|
||||||
| 2 | 15:10-15:20 | 讨论 |
临床大咖vs发表视角:观点分享 |
|
||||||
| 3 | 15:20-15:40 | 专题发言 |
血液领域高质量研究2 |
|
||||||
| 4 | 15:40-15:50 | 讨论 |
临床大咖vs发表视角:观点分享 |
|
||||||
| 5 | 15:50-16:10 | 专题发言 |
中国真实世界数据 |
|
||||||
| 6 | 16:10-16:20 | 讨论 |
临床大咖vs发表视角:观点分享 |
|
||||||
| 1 | 16:20-16:35 | 专题发言 |
2026最新方法学趋势 |
|
||||||||
| 2 | 16:35-16:45 | 讨论 |
共议:方法学创新如何赋能科研实践? |
|
||||||||
| 1 | 13:30-13:40 | 致辞 |
开幕致辞 |
|
||||||
| 1 | 13:40-14:00 | 专题发言 |
维奈克拉增强 γδ T 细胞抗AML的作用及机制研究 |
|
||||
| 2 | 14:00-14:20 | 专题发言 |
骨髓瘤治疗格局的改变 |
|
||||
| 3 | 14:20-14:40 | 专题发言 |
噬血细胞综合征移植预处理方案改良探索 |
|
||||
| 4 | 14:40-15:00 | 专题发言 |
靶向治疗时代异基因移植在ALL中的应用 |
|
||||
| 5 | 15:00-15:20 | 讨论 |
讨论 |
|
||||
| 1 | 15:20-15:40 | 专题发言 |
基于不同分子亚型AML异基因造血干细胞移植探讨 |
|
||||||||
| 2 | 15:40-16:00 | 专题发言 |
复杂血液病与移植并发症救治实践与思考 |
|
||||||||
| 3 | 16:00-16:20 | 专题发言 |
CART联合造血干细胞移植治疗血液肿瘤 |
|
||||||||
| 4 | 16:20-16:40 | 专题发言 |
育龄期女性HSCT后卵巢功能早衰的高危因素及生育功能保护 |
|
||||||||
| 5 | 16:40-17:00 | 专题发言 |
成人血液肿瘤单份脐带血移植的临床探索 |
|
||||||||
| 6 | 17:00-17:20 | 讨论 |
讨论 |
|
||||||||